SAMSUNG BIOLOGICS CO.,LTD. Logo

SAMSUNG BIOLOGICS CO.,LTD.

A CDMO providing end-to-end development and manufacturing services for the biopharma industry.

207940 | KO

Overview

Corporate Details

ISIN(s):
KR7207940008
LEI:
Country:
South Korea
Address:
인천광역시 연수구 송도바이오대로 300, 인천광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Samsung Biologics is a fully integrated contract development and manufacturing organization (CDMO) providing end-to-end services to the global biopharmaceutical industry. The company offers a comprehensive service suite from late discovery, cell line and process development to large-scale, CGMP-compliant manufacturing of drug substance (DS) and drug product (DP). Its offerings also include analytical testing services and development support for new modalities such as antibody-drug conjugates (ADCs) and mRNA. Leveraging advanced infrastructure and a strong regulatory track record, Samsung Biologics supports its clients, which include many of the world's leading pharmaceutical companies, from clinical development through to commercial supply.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-11 00:00
Registration Form
[기재정정]증권신고서(분할)
Korean 4.7 MB
2025-09-09 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 8.2 KB
2025-09-08 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-09-05 00:00
Environmental & Social Information
지속가능경영보고서등관련사항(자율공시)
Korean 16.8 KB
2025-09-02 00:00
Registration Form
[기재정정]증권신고서(분할)
Korean 5.2 MB
2025-09-01 00:00
Related Party Transaction
대규모기업집단현황공시[분기별공시(개별회사용)]
Korean 10.2 KB
2025-09-01 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-09-01 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.9 KB
2025-08-26 00:00
Regulatory News Service
단일판매ㆍ공급계약체결(자율공시)
Korean 7.7 KB
2025-08-25 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 37.5 KB
2025-08-22 00:00
M&A Activity
[기재정정]주요사항보고서(회사분할결정)
Korean 56.1 KB
2025-08-22 00:00
Registration Form
증권신고서(분할)
Korean 4.5 MB
2025-08-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 4.5 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 5.0 MB
2025-08-13 00:00
Regulatory News Service
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
Korean 11.3 KB

Automate Your Workflow. Get a real-time feed of all SAMSUNG BIOLOGICS CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SAMSUNG BIOLOGICS CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SAMSUNG BIOLOGICS CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Oncopeptides Logo
Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.
Sweden
ONCO
Onesano S.A. Logo
Develops patented nutritional products for humans, animals, and agriculture.
Poland
SKT
OnKure Therapeutics, Inc. Logo
Developing less toxic, tumor-agnostic kinase inhibitors for precision cancer therapy.
United States of America
OKUR
ONO PHARMACEUTICAL CO., LTD. Logo
Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.
Japan
4528
OPKO Health Inc. Logo
Provides clinical diagnostics & develops novel therapies for serious & pediatric diseases.
Israel
OPK
OPKO HEALTH, INC. Logo
A biopharma and diagnostics firm offering novel therapies and full-service clinical lab testing.
United States of America
OPK
Opthea Ltd Logo
Biopharma that discontinued its wet AMD therapy after its lead drug failed Phase 3 trials.
United States of America
OPT
OPTUS Pharmaceutical Co., Ltd. Logo
Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.
South Korea
131030
Opus Genetics, Inc. Logo
Developing gene therapies for inherited retinal diseases and other blinding conditions.
United States of America
IRD
ORAGENICS INC Logo
Biotech developing intranasal drugs for concussion and other brain disorders.
United States of America
OGEN

Talk to a Data Expert

Have a question? We'll get back to you promptly.